0.71
+0.319(+81.59%)
Currency In USD
Address
2223 Avenida De La Playa
La Jolla, CA 92037
United States of America
Phone
858 412 5302
Website
Sector
Healthcare
Industry
Biotechnology
Employees
35
First IPO Date
October 12, 2018
| Name | Title | Pay | Year Born |
| Mr. Bruce D. Steel C.F.A. | Co-Founder, President, Chief Executive Officer & Director | 471,340 | 1966 |
| Mr. Daniel Mark Bradbury | Executive Chairman | 164,000 | 1961 |
| Ms. Christine Zedelmayer M.B.A., P.M.P. | Senior Vice President & Chief Operating Officer | 415,300 | 1970 |
| Dr. Stephen Connelly Ph.D. | Chief Scientific Officer & Director | 428,490 | 1982 |
| Dr. Matthew Ritter Ph.D. | Senior Vice President of Corporate Development | 0 | N/A |
| Mr. Jason A. Keyes | Chief Financial Officer | 0 | 1971 |
| Penny Tom | Senior Vice President of Finance & Principal Accounting Officer | 0 | N/A |
| Mr. Joel M. Rothman | Chief Development Officer | 0 | 1969 |
| Dr. Lisette Acevedo | Vice President of Clinical Development | 0 | N/A |
| Mr. Michael Moore | Vice President of Investor Relations & Corporate Communications | 0 | N/A |
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.